ReviewMedical oncology (Northwood, London, England)2011

Should adjuvant trastuzumab be offered in very early-stage (pT1a/bN0M0) HER2-neu-positive breast cancer? A current debate.

Fausto Petrelli et al.PubMed ↗Publisher ↗

No numbers read from the abstract.